RSH.AX Respiri (ASX) A$0.033 pre-market oversold bounce: watch A$0.07 target 04 Feb 2026

RSH.AX stock opens pre-market at A$0.033, trading well below its 50-day and 200-day averages and setting a classic oversold bounce setup. Volume today is 579,396 shares versus an average of 870,341, keeping liquidity thin. In Australia on the ASX, Respiri Limited faces tight fundamentals with EPS -0.01 and a price to earnings near -3.30, but our short-term view looks for a technical rebound toward obvious resistance at A$0.05 and a model target near A$0.07.

Price snapshot and market context for RSH.AX stock

Respiri (RSH.AX) trades on the ASX in Australia at A$0.033 pre-market. The stock’s 52-week range is A$0.02 to A$0.10, with a market cap of A$51,984,240.00. Daily range today is A$0.03 to A$0.033, and year-to-date movement is down 58.23%, underlining the oversold condition.

Sector context: Respiri sits in Healthcare, Medical – Devices. The small-cap healthcare group has shown mixed performance, which keeps investor attention focused on product adoption and recurring revenue trends.

Why an oversold bounce matters for RSH.AX stock

An oversold bounce offers short-term traders a defined risk-reward opportunity. RSH.AX stock has slid from its 200-day average of A$0.05 and a 50-day average of A$0.04, a drop that can trigger mean-reversion trades.

With trading volume at 579,396 today, a sudden uptick in buyer interest could push price back toward short-term resistance at A$0.05 and then A$0.07. That path gives a measurable upside while allowing tight stops below the year low of A$0.02.

RSH.AX stock fundamentals and valuation

Respiri’s trailing EPS is -0.01 and reported PE around -3.30, reflecting ongoing losses. Price-to-sales and price-to-book ratios are high, at roughly 113.77 and 12.74 respectively, which signals stretched valuation relative to revenue and equity.

Operating cash flow per share is negative at -0.01 and the current ratio sits at 1.18, so the balance sheet is tight but not insolvent. These metrics show why any rally needs revenue or partnership proof to sustain.

Technical setup and risk for RSH.AX stock technicals

Technical indicators show an oversold pattern and low momentum readings. Average volume is 870,341 shares, so above-average prints will be needed to validate moves. Key near-term support is A$0.03 and the year low at A$0.02.

Traders should watch for a volume-confirmed move above A$0.04 to signal a real bounce. Given very low free float and tiny staff headcount, moves can be fast and volatile, increasing execution risk.

Meyka AI grade and RSH.AX stock forecast

Meyka AI rates RSH.AX with a score out of 100: 63.61 (B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and we are not financial advisors.

Meyka AI’s forecast model projects a 12‑month median price near A$0.07, versus the current A$0.033, implying an upside of 112.12%. Forecasts are model-based projections and not guarantees. Use them with risk controls and monitor upcoming earnings and product updates.

Practical trading plan and price targets for RSH.AX stock outlook

Short-term target for an oversold bounce: A$0.05 initial resistance, then A$0.07 as a stretch target. Stop-loss consideration: under A$0.02 to cap downside. Position sizing should be small given market cap A$51,984,240.00 and tight liquidity.

Longer-term investors need revenue growth or clinical validation. Near-term catalysts include product adoption updates and the next earnings which may move sentiment materially.

Final Thoughts

RSH.AX stock trades at A$0.033 pre-market on 04 Feb 2026 and sits in an oversold setup that can produce a short-term bounce. The immediate technical path is clear: a volume-led rise above A$0.04 opens a run to A$0.05 and the Meyka AI model target near A$0.07. Meyka AI’s forecast model projects A$0.07, an implied upside of 112.12% from today’s price, but this projection is model-based and not a guarantee. Fundamentals show negative EPS -0.01, high price-to-sales 113.77, and limited cash per share, so any rally needs improving revenue or product news to hold. For traders, use tight stops and limit exposure. For investors, monitor earnings, product milestones, and liquidity before increasing allocation. Meyka AI provides this as an AI-powered market analysis platform insight, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.